#mounjaro weight loss 2.5

[productview]

Mengara Weight Loss: A New Drug with Promising Results

Uncover the breakthrough in weight loss with Mengara, the game-changing drug that delivers exceptional results. Find out how this revolutionary medication can transform your life. Introduction Stoutness, a worldwide pandemic, presents extreme wellbeing gambles, including coronary illness, stroke, type 2 diabetes, and certain tumors. While various weight loss medications exist, their side effects…

[peptide-ltd]

The most complete dosage for you to learn how touse Tirzepatide

Polypeptide.ltd as a Tirzepatide supplier. We only good at producing high quality Tirzepatide powder. The Tirzepatide powder dosage and administration information provided here is for informational purposes only and should not be considered as medical advice. The dosing of tirzepatide can vary based on its intended use for type 2 diabetes and weight loss. Based on multiplestudies, here is a general tirzepatide dosage guide:

Tirzepatide dosage for Type 2 Diabetes

Tirzepatide(Mounjaro) is used as an adjunct to diet and exercise to improve glycemic control inadults with type 2 diabetes mellitus. The dosing typically follows this pattern:

❶Initial Dose: 2.5 mg subcutaneous injection once a week for 4 weeks.

❷Maintenance Dose: Increase to 5 mg subcutaneous injection once a week after the initial 4weeks.

❸Titration: If additional glycemic control is needed, the dose can be increased in 2.5 mgincrements after at least 4 weeks at the current dose.

❹Maximum Dose: The maximum recommended dose is 15 mg subcutaneous injection once aweek. Please note that the initial 2.5 mg dose is for treatment initiation and is not effective for glycemic control. You will need to adjust your dosage based on your response and needs.

Tirzepatide dosage for Weight Loss

Tirzepatide has been shown to help lose weight in overweight patients. The dosing for weight lossmay be different and can be informed by clinical trials such as SURMOUNT-1 and SURMOUNT-2. Polypeptide.ltd as Tizepatide powder manufacturer don’t teach how to use Tirzepatide. But a potential weight loss protocol could be:

❶Initial Dose: 2.5 mg subcutaneous injection once a week for the first four weeks.

❷Progressive Increase: Increase the dose to 5 mg weekly in weeks 5-8, 7.5 mg weekly in weeks9-12, and 10 mg weekly in weeks 13-16.

❸Further Adjustment: Depending on individual response and tolerance, consider increasing to 12.5 mg weekly in weeks 17-20, and up to a maximum dose of 15 mg weekly from week 21 onwards.

❹Frequency and Duration: Administer once-weekly subcutaneous injections, and studies using this protocol have lasted 24-72 weeks.

It’s essential to consult your healthcare provider before making any changes to your medication dosage. This guide is a general overview and should not replace personalized medical advice. Your healthcare provider will determine the most appropriate dosing regimen for your specific condition and needs.

[mobidoctormalta]

Mounjaro For Weight Loss

Should You Try Mounjaro for Weight Loss? Answering Your Burning Questions

In the quest for effective weight loss solutions, mounjaro for weight loss (tirzepatide) has emerged as a promising option. But before you begin this treatment, having a few questions and concerns is natural. 

This comprehensive guide will address common queries about Mounjaro to help you make an informed decision.

Understanding Mounjaro: What Is It?

Mounjaro is a medication containing tirzepatide, developed by Eli Lilly. It belongs to the class of GLP-1 receptor agonists, similar to other drugs like Ozempic (semaglutide) and Wegovy (semaglutide). 

Originally designed for managing type 2 diabetes, Mounjaro has shown remarkable effectiveness in aiding weight loss.

How Does Mounjaro Work?

Tirzepatide works by mimicking the action of glucagon-like peptide-1 (GLP-1), a hormone that regulates blood sugar levels and appetite.

It stimulates insulin secretion, suppresses glucagon secretion (which reduces blood sugar levels), and slows gastric emptying, leading to decreased appetite and increased feelings of fullness; these mechanisms contribute to weight loss and improved glycemic control.

The Benefits of Mounjaro for Weight Loss

Clinical trials have demonstrated significant weight loss outcomes with Mounjaro. Participants experienced an average reduction of up to 21% of their initial body weight when combined with a reduced-calorie diet and increased physical activity. 

Additionally, Mounjaro has shown effectiveness in improving diabetes management by reducing HbA1c levels, a long-term measure of blood sugar control.

Answering Your Burning Questions:

To let you clearly understand whether the Mounjaro prescription is suitable for your weight loss goals and overall health, here are a few more insights:

1. Is Mounjaro Suitable for Everyone?

Mounjaro is prescribed for adults with type 2 diabetes who are struggling with weight management. However, its use may be extended for individuals without diabetes seeking weight loss solutions, under the guidance of a healthcare professional.

2. What Results Can I Expect with Mounjaro?

Results may vary from person to person, but clinical trials have shown significant weight loss (20% or more) over one year with Mounjaro treatment.

3. How Should Mounjaro Be Used?

Mounjaro is typically given as a weekly injection, starting with an initial dose of 2.5 mg. The dosage can be adjusted gradually based on individual response and tolerability, under medical supervision.

4. Are There Any Side Effects of Mounjaro?

Common side effects of Mounjaro may include nausea, vomiting, diarrhea, and decreased appetite. It is common for these side effects to be mild or moderate and to improve with time. Nevertheless, it's crucial to talk to your healthcare provider about any concerns.

5. Should Mounjaro Be Combined with Lifestyle Changes?

Yes! Mounjaro works best alongside lifestyle modifications such as a balanced diet, regular exercise, and adequate sleep. These lifestyle changes can enhance the effectiveness of Mounjaro and promote long-term weight management success.

Final Thoughts

Mounjaro offers a promising option for individuals struggling with weight management, whether they have diabetes or not. 

However, like any medication, it's essential to weigh the potential benefits against the risks and consider individual factors such as medical history, lifestyle, and treatment goals.

If you're considering Mounjaro for weight loss, consult��with a healthcare provider at Mobi Doctor to discuss whether it's the right choice.

Together, you can explore your options, address any concerns, and develop a personalized treatment plan to support your weight loss journey!

[drangelo123]

Buy Zepbound Online

Buy Zepbound (Tirzepatide) Injection For Obesity

Buy Zepbound Online, It is a medication used to help manage blood sugar and promote weight loss in adults with type 2 diabetes. It is a once-weekly injection that combines two hormones called GLP-1 and GIP1. The generic name for Zepbound is Tirzepatide, and it is sometimes sold under the brand name Mounjaro. Zepbound For Sale, It contains the active ingredient Tirzepatide, a glucagon-like peptide-1 (GLP-1) receptor agonist and a dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonist. The injection is formulated as a solution and is available in doses of 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg per 0.5 mL single-dose pen.

[eazy-group]

Dr. Felicia lost 25 pounds

New Post has been published on https://eazydiet.net/dr-felicia-lost-25-pounds/

Dr. Felicia lost 25 pounds

Transformation of the Day: Dr. Felicia lost 25 pounds. This grandmother of six is was determined to reclaim her health and be there to see her grandchildren growup and thrive. She took action by learning about how processed foods affect the body and reached out to her doctor who prescribed her Mounjaro.

Social Media:  Facebook: Drfeliciariggs Instagram: @DrRiggs66 TikTok: @DrRo66

Hi! My name is Dr. Felicia Riggs, and I have battled with weight for way too long. I knew that it was time to make a change when I looked up and realized that I was taking the “dirty cocktail” of high blood, cholesterol, and diabetic medications.  

Being the grandmother of six and one on the way, I really started thinking about the quality of the rest of my years and being able to spend time with them and watch them grow up. 

Six years ago, I was really at a low point in my life (newly divorced and battling depression) when I journaled about how I wanted my life to look like in five years without the slightest sight of it coming true. One of the many things I wanted to do was lose weight and get my health back on track. 

This past summer, I had been hearing about the success people were having on the Tirzepitides for diabetes and weight loss and decided to ask my primary doctor about it. I will not lie: I LOVED to eat and had NO self-control. Sit a basket of bread rolls or a bag of potato chips in front of me and it was OVER. I failed time after time whenever I tried to eat healthier and began to take it on as a personality defect. 

As I studied more and more, I learned that those foods were engineered to make us overeat and crave more, so it was by design that I would fail—it felt like an endless cycle. 

In October, my doctor prescribed me Mounjaro at 2.5 ml at first and then to 5 ml. After about a week, the cravings were mitigated, and I started replacing chips with fruits and nuts. I then started paying close attention to portion sizes and calories as the injections were highly effective on curbing my appetite. 

My starting weight was 240 pounds. Three months later, I have managed to lose 25 pounds, so I am currently at 215 at 5’3”. My ultimate goal is to live in “One-derland” by losing at least 25 more before moving into a maintenance phase.

At this point, I have embraced better eating habits (cooking at home, no fast foods, fried foods, processed foods, or sugar) as part of my life. I do not like seafood, so I mainly eat chicken, chicken sausage for breakfast or chicken-based soups. I also eat veggie-based pasta, salads, and small portions of carbs for lunch. Sometimes, I fast in the evenings.  

As far as working out, the Lord is still working on me, but I do enjoy a 20-30 minute walk at least three times a week. I LOVE water aerobics in the summer. I am going to pick up my Hoolahoop, put on some African beats, and focus on toning with a weight bar.

I have learned through this process that I CAN do whatever I set my mind to. I have also learned that if you have a vision for your life and you become intentional, the HELP is there and WILL manifest itself! I wrote the EXACT weight I wanted to be, and I am SO excited that I am almost there!

<![CDATA[.prevNextBtnbackground-image:none;]]>

window.fbAsyncInit = function() FB.init( appId : '1531644400444480', xfbml : true, version : 'v2.2' ); ;

(function(d, s, id) var js, fjs = d.getElementsByTagName(s)[0]; if (d.getElementById(id)) return; js = d.createElement(s); js.id = id; js.src = "https://connect.facebook.net/en_US/sdk.js"; fjs.parentNode.insertBefore(js, fjs); (document, 'script', 'facebook-jssdk')); Source link

[xtruss]

Anti-Obesity Drugs Can Shrink More Than Patients

— By Aimee Donnellan and Robert Cyran | September 20, 2023 | Reuters

Boxes of Ozempic and Mounjaro, semaglutide and tirzepatide injection drugs used for treating type 2 diabetes and made by Novo Nordisk and Lilly, is seen at a Rock Canyon Pharmacy in Provo, Utah, U.S. March 29, 2023. Reuters/George Frey Acquire Licensing Rights

London, UK/New York, USA — Starry-eyed venture capitalists love to talk about how promising startups might capture a chunk of a giant total addressable market (TAM). This concept can also work in reverse, though. New anti-obesity drugs have the potential to transform public health, while obliterating demand for products and services from the medical, food and fitness industries. Think of them as total unaddressable markets (TUM).

Drugs developed by Novo Nordisk (NOVOb.CO) and Eli Lilly (LLY.N) appear to be the first truly effective diet treatments. They work by targeting receptors in the brain that reduce appetite and help people feel fuller for longer. Originally developed to tackle diabetes, they’re gaining traction as treatments for obesity. In one clinical trial, patients taking Eli Lilly’s soon-to-be-launched weight-loss drug lost about 50 pounds (23 kg). The benefits for public health are potentially huge. In August, Novo said Wegovy, its obesity drug, reduced the incidence of serious cardiovascular events like strokes and heart attacks by 20% in overweight patients who have a history of heart disease but don’t have diabetes.

Sales are already soaring. Last year, Novo sold nearly $2.5 billion worth of Wegovy and Ozempic, its treatment for people with diabetes. Analysts expect that figure to balloon to $16 billion by 2027, according to forecasts compiled by Visible Alpha. Demand for the medicines, collectively known as GLP-1 drugs, far exceeds what manufacturers can currently produce. Yet excitement has lifted Novo’s market capitalisation to $420 billion, making it Europe’s most valuable company. Lilly, whose diabetes treatment is called Mounjaro, has seen its market value nearly double to more than $500 billion in under 18 months.

Reuters Graphics Reuters Graphics

Such a dramatic revolution in public health will also produce losers, though. The drugs are designed to suppress appetite, mimicking a gut hormone which is released after eating. During trials, patients showed reduced appetite and even an aversion towards food generally. This has the potential to affect giant groups such as Switzerland’s Nestlé (NESN.S), Cadbury and Oreo maker Mondelez International (MDLZ.O), and Kraft Heinz (KHC.O). These companies dominate a global market for snacks which is currently worth more than half a trillion dollars in revenue per year and is expected by Fortune Business Insights to expand to nearly $840 billion by 2029. Fast food groups like McDonald’s (MCD.N), Burger King and KFC owner Yum Brands (YUM.N) could also face shrinking or shifting demand.

The potential impact on the medical industry could be even bigger. Over 40% of Americans are obese according to the Centers for Disease Control and Prevention, and that number has increased by nearly 40% over two decades. Obese people are more likely to suffer from cardiovascular disease, various cancers, arthritis and dementia. In 2016 the Milken Institute estimated the medical costs associated with obesity in the United States at nearly $500 billion a year. A 2021 study published in the BMJ projected that costs from reduced health and higher absenteeism worldwide would rise 50% by 2060.

The adoption of anti-obesity drugs remains hard to gauge. At a cost of about $1,000 per month it’s unclear whether insurers and public health authorities will fund widespread treatment. Side effects can also be harsh. Only about a third of those who started taking the drugs for obesity were still doing so a year later, according to one analysis.

Any destructive impact is therefore likely to be gradual. Even so, investors are beginning to fret. Breakingviews scanned transcripts of corporate earnings calls, presentations and other events tracked by LSEG for mentions of Wegovy, Ozempic and Mounjaro – excluding those hosted by Novo and Lilly. In 2022 there were 18 such events. So far this year, at least one of the drugs has been mentioned 71 times.

Reuters Graphics Reuters Graphics

Among the potential losers are firms like ResMed (RMD.N) and Inspire Medical Systems (INSP.N), which make products that treat sleep apnea, a condition where patients intermittently stop breathing while asleep. Around 70% of sufferers are obese. On a call with investors in August, ResMed CEO Michael Farrell said he thought weight-loss drugs wouldn’t have a major impact on the company’s future sales because the treatment is harsh and its cost would discourage many patients from taking it long term, while awareness of the effects of obesity could push patients towards apnea treatment. Even so, ResMed’s stock has since lost about a third of its value.

Meanwhile, companies selling joint replacements such as Zimmer Biomet (ZBH.N) and Smith+Nephew (SN.L) could see their $25 billion and $11 billion values slimmed. These two firms earn about two-thirds and 30% of their revenue, respectively, from hip and knee implants. One study estimated about a quarter of surgical cases involving knees could be avoided if patients weren’t overweight. Rival weight management treatments also look vulnerable. Since June 2021, when Novo Nordisk’s first obesity drug gained regulatory approval, shares of WW International (WW.O), formerly Weight Watchers, have collapsed about 70%, despite the company unveiling a plan to distribute weight-loss drugs.

Reuters Graphics Reuters Graphics

Economic destruction could spread further afield, too. Anecdotal reports and trials on animals suggest GLP-1 drugs may also dampen urges beyond snacking, including consuming alcohol, nicotine and possibly engaging in other addictive behaviors like gambling.

These changes may have limited impact or affect only a small number of users. But any reduction in addictions could have big effects. The gambling and alcohol industries tend to display so-called Pareto distributions, where a few users provide most of the profit. In England, for example, 4% of drinkers account for 23% of the industry’s revenue, according to a study in the journal Addiction. And the top 20% most engaged gamblers using an online casino operated by the Canadian government made up 92% of revenue and 90% of losses.

Widespread adoption of GLP-1 drugs could also produce corporate winners as consumers divert cash previously spent on food and medical care. Plastic surgeons may benefit if patients seek nips and tucks following weight loss. Dating services like Match and Grindr (GRND.N) may attract newly confident users. Fashion brands and sporting goods groups could get a lift from people seeking new wardrobes or embracing athletic pursuits. Yet even as Novo, Lilly and others see their addressable markets expand, some companies will see theirs shrink. For investors, the TUM may be just as important as the TAM.